AAAAAA
Results:
1-7
|
Results: 7
Authors:
Ding, ZH
Parchment, RE
LoRusso, PM
Zhou, JY
Li, J
Lawrence, TS
Sun, Y
Wu, GS
Citation: Zh. Ding et al., The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways, CLIN CANC R, 7(11), 2001, pp. 3336-3342
Authors:
Prakash, S
Foster, BJ
Meyer, M
Wozniak, A
Heilbrun, LK
Flaherty, L
Zalupski, M
Radulovic, L
Valdivieso, M
LoRusso, PM
Citation: S. Prakash et al., Chronic oral administration of CI-994: A phase 1 study, INV NEW DR, 19(1), 2001, pp. 1-11
Authors:
LoRusso, PM
Foster, BJ
Wozniak, A
Heilbrun, LK
McCormick, JI
Ruble, PE
Graham, MA
Purvis, J
Rake, J
Drozd, M
Lockwood, GF
Corbett, TH
Citation: Pm. Lorusso et al., Phase I pharmacokinetic study of the novel antitumor agent SR233377, CLIN CANC R, 6(8), 2000, pp. 3088-3094
Authors:
Keyes, KA
Albella, B
LoRusso, PM
Bueren, JA
Parchment, RE
Citation: Ka. Keyes et al., Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond, CLIN CANC R, 6(6), 2000, pp. 2474-2481
Authors:
Blum, JL
Jones, SE
Buzdar, AU
LoRusso, PM
Kuter, I
Vogel, C
Osterwalder, B
Burger, HU
Brown, CS
Griffin, T
Citation: Jl. Blum et al., Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer, J CL ONCOL, 17(2), 1999, pp. 485-493
Authors:
Shields, AF
Philip, PA
LoRusso, PM
Ferris, AM
Zalupski, MM
Citation: Af. Shields et al., Phase II study of CI-958 in colorectal cancer, CANC CHEMOT, 43(2), 1999, pp. 162-164
Authors:
LoRusso, PM
Parchment, R
Demchik, L
Knight, J
Polin, L
Dzubow, J
Behrens, C
Harrison, B
Trainor, G
Corbett, TH
Citation: Pm. Lorusso et al., Preclinical antitumor activity of XK469 (NSC 656889), INV NEW DR, 16(4), 1998, pp. 287-296
Risultati:
1-7
|